Effect of receiving a customizable brochure on breast cancer patients' knowledge about their diagnosis and treatment: A randomized clinical trial.
Latin America
breast cancer
patient education
shared decision-making
written information
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
04
04
2023
received:
25
10
2022
accepted:
29
05
2023
medline:
14
8
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
Patients' lack of knowledge about their own disease may function as a barrier to shared decision-making and well-being. This study aimed to evaluate the impact of written educational materials on breast cancer patients. This multicenter, parallel, unblinded, randomized trial included Latin American women aged ≥18 years with a recent breast cancer diagnosis yet to start systemic therapy. Participants underwent randomization in a 1:1 ratio to receive a customizable or standard educational brochure. The primary objective was accurate identification of molecular subtype. Secondary objectives included identification of clinical stage, treatment options, participation in decision-making, perceived quality of information received, and illness uncertainty. Follow-up occurred at 7-21 and 30-51 days post-randomization. gov identifier: NCT05798312. One hundred sixty-five breast cancer patients with a median age of 53 years and 61 days from diagnosis were included (customizable: 82; standard: 83). At first available assessment, 52%, 48%, and 30% identified their molecular subtype, disease stage, and guideline-endorsed systemic treatment strategy, respectively. Accurate molecular subtype and stage identification were similar between groups. Per multivariate analysis, customizable brochure recipients were more likely to identify their guideline-recommended treatment modalities (OR: 4.20,p = 0.001). There were no differences between groups in the perceived quality of information received or illness uncertainty. Customizable brochure recipients reported increased participation in decision-making (p = 0.042). Over one third of recently diagnosed breast cancer patients are incognizant of their disease characteristics and treatment options. This study demonstrates a need to improve patient education and shows that customizable educational materials increase patients' understanding of recommended systemic therapies according to individual breast cancer characteristics.
Sections du résumé
BACKGROUND
Patients' lack of knowledge about their own disease may function as a barrier to shared decision-making and well-being. This study aimed to evaluate the impact of written educational materials on breast cancer patients.
METHODS
This multicenter, parallel, unblinded, randomized trial included Latin American women aged ≥18 years with a recent breast cancer diagnosis yet to start systemic therapy. Participants underwent randomization in a 1:1 ratio to receive a customizable or standard educational brochure. The primary objective was accurate identification of molecular subtype. Secondary objectives included identification of clinical stage, treatment options, participation in decision-making, perceived quality of information received, and illness uncertainty. Follow-up occurred at 7-21 and 30-51 days post-randomization.
CLINICALTRIALS
gov identifier: NCT05798312.
RESULTS
One hundred sixty-five breast cancer patients with a median age of 53 years and 61 days from diagnosis were included (customizable: 82; standard: 83). At first available assessment, 52%, 48%, and 30% identified their molecular subtype, disease stage, and guideline-endorsed systemic treatment strategy, respectively. Accurate molecular subtype and stage identification were similar between groups. Per multivariate analysis, customizable brochure recipients were more likely to identify their guideline-recommended treatment modalities (OR: 4.20,p = 0.001). There were no differences between groups in the perceived quality of information received or illness uncertainty. Customizable brochure recipients reported increased participation in decision-making (p = 0.042).
CONCLUSIONS
Over one third of recently diagnosed breast cancer patients are incognizant of their disease characteristics and treatment options. This study demonstrates a need to improve patient education and shows that customizable educational materials increase patients' understanding of recommended systemic therapies according to individual breast cancer characteristics.
Identifiants
pubmed: 37317676
doi: 10.1002/cam4.6215
pmc: PMC10417173
doi:
Banques de données
ClinicalTrials.gov
['NCT05798312']
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15612-15627Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Transl Behav Med. 2019 Jul 16;9(4):638-645
pubmed: 29986120
Cancer Nurs. 2018 Nov/Dec;41(6):484-490
pubmed: 29489477
Cancer. 2015 Mar 1;121(5):724-32
pubmed: 25624186
J Glob Health. 2018 Jun;8(1):010419
pubmed: 29740502
Oncol Nurs Forum. 2019 Jan 13;46(1):E22-E37
pubmed: 30547960
Cancer Med. 2023 Jul;12(14):15612-15627
pubmed: 37317676
Oncol Nurs Forum. 2018 Nov 1;45(6):748-760
pubmed: 30339152
Clin Transl Oncol. 2011 Jun;13(6):401-10
pubmed: 21680301
Oncol Nurs Forum. 2016 Mar;43(2):180-9
pubmed: 26906129
Breast Cancer Res Treat. 2017 Sep;165(2):247-260
pubmed: 28573448
Med Decis Making. 2016 Aug;36(6):714-25
pubmed: 26957566
J Palliat Med. 2016 Mar;19(3):314-7
pubmed: 26855201
Gac Sanit. 2020 Jul - Aug;34(4):399-402
pubmed: 30473252
Eur J Cancer. 2010 Oct;46(15):2726-38
pubmed: 20674333
Patient Educ Couns. 2010 Jul;80(1):94-9
pubmed: 19879711
Psychooncology. 2015 Feb;24(2):130-7
pubmed: 24953538
J Cancer Surviv. 2013 Jun;7(2):211-8
pubmed: 23417167
J Cancer Educ. 2014 Jun;29(2):270-7
pubmed: 24343267
Health Expect. 2015 Dec;18(6):2143-53
pubmed: 24593044
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
Gynecol Oncol. 2006 Mar;100(3):495-500
pubmed: 16242759
J Oncol Pract. 2016 Jun;12(6):e613-25
pubmed: 27165488
J Cancer Surviv. 2012 Mar;6(1):20-32
pubmed: 21735277
Clin Breast Cancer. 2019 Jun;19(3):178-187.e3
pubmed: 30685264
Eur J Oncol Nurs. 2018 Dec;37:35-42
pubmed: 30473049
Surgery. 2015 Sep;158(3):669-75
pubmed: 26032819